EUR 53.4
(2.5%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 81.05 Million EUR | 109.2% |
2022 | 51.53 Million EUR | -29.88% |
2021 | -12.42 Million EUR | -153.25% |
2020 | -5.9 Million EUR | -254.92% |
2019 | -1.36 Million EUR | -116.94% |
2018 | 8.02 Million EUR | 1124.41% |
2017 | -751.5 Thousand EUR | 76.58% |
2016 | -3.34 Million EUR | -309.07% |
2015 | 1.59 Million EUR | -17.65% |
2014 | 1.94 Million EUR | 129.28% |
2013 | -6.63 Million EUR | -248.76% |
2012 | -1.97 Million EUR | -55.01% |
2011 | -1.22 Million EUR | -22.08% |
2010 | -1 Million EUR | -446.7% |
2009 | -183.85 Thousand EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -17.51 Million EUR | 0.0% |
2023 Q2 | 7.39 Million EUR | 0.0% |
2023 Q4 | -5.93 Million EUR | 0.0% |
2023 FY | - EUR | 109.2% |
2022 FY | - EUR | -29.88% |
2022 Q2 | -7.42 Million EUR | 0.0% |
2022 Q4 | -8.44 Million EUR | 0.0% |
2021 Q2 | -9.71 Million EUR | 0.0% |
2021 Q4 | -7.33 Million EUR | 0.0% |
2021 FY | - EUR | -153.25% |
2020 Q4 | -3.93 Million EUR | 0.0% |
2020 FY | - EUR | -254.92% |
2020 Q2 | -886.3 Thousand EUR | 0.0% |
2019 Q2 | -242.77 Thousand EUR | 0.0% |
2019 FY | - EUR | -116.94% |
2019 Q4 | -1.11 Million EUR | 0.0% |
2018 Q4 | -586.25 Thousand EUR | 0.0% |
2018 Q2 | 8.61 Million EUR | 0.0% |
2018 FY | - EUR | 1124.41% |
2017 Q4 | 1.72 Million EUR | 0.0% |
2017 FY | - EUR | 76.58% |
2017 Q2 | -2.5 Million EUR | 0.0% |
2016 FY | - EUR | -309.07% |
2016 Q2 | -817.71 Thousand EUR | 0.0% |
2016 Q4 | -2.52 Million EUR | 0.0% |
2015 Q4 | -434.51 Thousand EUR | 0.0% |
2015 Q2 | 2.03 Million EUR | 0.0% |
2015 FY | - EUR | -17.65% |
2014 FY | - EUR | 129.28% |
2014 Q4 | -1.34 Million EUR | 0.0% |
2014 Q2 | 3.28 Million EUR | 0.0% |
2013 Q3 | -1.65 Million EUR | 0.0% |
2013 FY | - EUR | -248.76% |
2013 Q4 | 485.35 Thousand EUR | 129.26% |
2013 Q2 | -1.65 Million EUR | 0.0% |
2013 Q1 | -1.65 Million EUR | 0.0% |
2012 Q3 | -493.85 Thousand EUR | 0.0% |
2012 Q1 | -493.85 Thousand EUR | 0.0% |
2012 Q4 | -1.65 Million EUR | -235.82% |
2012 Q2 | -493.85 Thousand EUR | 0.0% |
2012 FY | - EUR | -55.01% |
2011 Q2 | -306.5 Thousand EUR | 0.0% |
2011 Q1 | -306.5 Thousand EUR | 0.0% |
2011 FY | - EUR | -22.08% |
2011 Q3 | -306.5 Thousand EUR | 0.0% |
2011 Q4 | -493.85 Thousand EUR | -61.13% |
2010 Q1 | -248.46 Thousand EUR | 0.0% |
2010 FY | - EUR | -446.7% |
2010 Q4 | -306.5 Thousand EUR | -23.36% |
2010 Q3 | -248.46 Thousand EUR | 0.0% |
2010 Q2 | -248.46 Thousand EUR | 0.0% |
2009 Q4 | -248.46 Thousand EUR | -440.57% |
2009 Q2 | -45.96 Thousand EUR | 0.0% |
2009 Q1 | -45.96 Thousand EUR | 0.0% |
2009 Q3 | -45.96 Thousand EUR | 0.0% |
2009 FY | - EUR | 0.0% |
2008 Q4 | -45.96 Thousand EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
BioNTech SE | 1.08 Billion EUR | 92.548% |
CureVac N.V. | -234.09 Million EUR | 134.625% |
Biotest Aktiengesellschaft | 179 Million EUR | 54.719% |
Biotest Aktiengesellschaft | 179 Million EUR | 54.719% |
BRAIN Biotech AG | -2.38 Million EUR | 3495.601% |
Heidelberg Pharma AG | -18.7 Million EUR | 533.291% |
Medigene AG | -14.58 Million EUR | 655.729% |